The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
Alejandra Martínez-TrillosMagda PinyolJulio DelgadoMarta AymerichMaria RozmanTycho BaumannMarcos González-DíazJesus M HernándezMiguel AlcocebaAnna MuntañolaMaria José TerolBlanca NavarroEva GinéPedro JaresSílvia BeàAlba NavarroDolors ColomerFerran NadeuEnrique ColadoAngel R PayerTomás García-CerecedoXosé S PuenteCarlos López-OtinElias CampoArmando López-GuillermoNeus VillamorPublished in: Leukemia & lymphoma (2017)
Small lymphocytic lymphoma (SLL) is considered as the non-leukemic form of presentation of chronic lymphocytic leukemia (CLL). We have compared the features, genomic alterations, and outcome of 890 patients with CLL and SLL. One hundred and thirteen patients presented as SLL and more frequently had unmutated-IGHV, CD38high, ZAP-70high, CD49dhigh, +12, alterations in genes of NOTCH1, cell cycle, RNA metabolism, and NFkB pathways than CLL. During the follow-up, 46% of SLL patients developed CLL. Time to first treatment (TTFT) was shorter in SLL (10-year: 75% vs 62%; p = .006). Binet stage, SLL, and IGHV were independent predictive factors for TTFT. Transformation to diffuse large B-cell lymphoma was higher (10-year: 12% vs 6%; p = .003), and overall survival was shorter in SLL (10-year: 55% vs 66%; p = .004). When A0 CLL patients were excluded, only CD38 and CD49d expression, +12, and 10-year TTFT remained different between the SLL and CLL patients. In summary, SLL showed only minor clinicobiological differences when compared with CLL in similar clinical stages.
Keyphrases
- chronic lymphocytic leukemia
- diffuse large b cell lymphoma
- end stage renal disease
- early stage
- newly diagnosed
- ejection fraction
- cell cycle
- chronic kidney disease
- cell proliferation
- prognostic factors
- squamous cell carcinoma
- epstein barr virus
- gene expression
- patient reported outcomes
- acute myeloid leukemia
- transcription factor
- binding protein
- rectal cancer